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Background: Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by hypertension in the
pulmonary arteries. PAH leads to symptoms such as shortness of breath, dizziness, leg edema and chest pain,
impacting heavily on quality of life. The aim of this systematic review and meta-analysis was to determine the effect
of exercise training to improve physical fitness and functionality in patients with PAH.
Methods: A search was conducted for controlled trials using the databases Medline, Embase, SPORT Discus and
Cochrane Central Register of Controlled Trials. Studies were included if at least 80% of the participants presented
with group 1 PAH and if the intervention consisted of an exercise training program of at least 3 weeks duration.
Data were extracted on study quality, participant and exercise intervention characteristics, and outcomes. Data were
pooled by the generic inverse variance method using random effect models and were expressed as weighted
means and 95% confidence intervals (CI).
Results: Of 110 identified abstracts, 5 studies with 106 patients (exercise: 53; control: 53; mean age 49.7 years) were
included. Disease severity ranged from mild to severe; 96 patients suffered from PAH, 10 patients had chronic
thromboembolic pulmonary hypertension. Exercise training led to an increase in 6 minute walk distance (72.5 m;
95% CI 46.0 m to 99.1 m; p < 0.0001) and peak oxygen uptake (2.16 mL/kg/min; 95% CI 2.16 to 3.93; p = 0.02). No
severe adverse events during exercise were reported.
Conclusions: Our findings suggest that an exercise training program positively influences exercise tolerance and
functional capacity in patients with PAH.
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Pulmonary arterial hypertension (PAH) is characterized
by changes in mostly the distal pulmonary arteries. This
causes an increase in pulmonary vascular resistance,
which in turn restricts the blood flow through the pul-
monary circulation [1,2]. In order to maintain the blood
flow, the pulmonary artery pressure increase which leads
to right ventricular overload, hypertrophy and dilatation
[1]. The physiologic response of the pulmonary vascula-
ture to exercise is different from normal in individuals* Correspondence: roselien.buys@faber.kuleuven.be
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unless otherwise stated.with PAH and they generally show a reduced exercise
capacity [3]. Advances in the understanding and manage-
ment of pulmonary arterial hypertension have enabled
earlier diagnosis and improved prognosis. However, des-
pite best available therapy, symptoms of exertional dys-
pnea and fatigue are commonly reported and result in a
reduced capacity to perform daily activities and impaired
quality of life.
Exercise training has demonstrated efficacy in individ-
uals with other respiratory and cardiovascular diseases
[4-7]. Historically, however, exercise training has not been
utilized as a form of therapy in PAH due to the perceived
risk of sudden cardiac death and the theoretical possibilityis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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vascular hemodynamics and deterioration in right heart
function. Now, with the advances in pharmacological
management, determining the safety and benefits of exer-
cise training in this population has become more relevant.
The Task Force for the Diagnosis and Treatment of Pul-
monary Hypertension of the European Society of Cardi-
ology and the European Respiratory Society therefore
state that more data are required in order to be able to
make recommendations regarding physical activity and
supervised rehabilitation in patients with PAH [1]. Re-
cently, some studies of supervised and home-based exer-
cise training in PAH have been published and it seems
worthwhile to summarize their results in order to provide
some evidence for the clinicians to rely on.
Therefore, the aim of this systematic review was to
apply the meta-analytic approach in controlled trials in
order to determine the effects of exercise training on
functional status and exercise capacity.
Methods
Literature search
A systematic literature search was conducted in the elec-
tronic Pubmed database from its inception to December
2013 using following terms: (medical subject heading
(MeSH-term)) ‘exercise’ or (MeSH term) ‘rehabilitation’
or (field term) ‘exercise training’ AND (MeSH-term)
‘pulmonary hypertension’ or (field term) ‘pulmonary ar-
terial hypertension’; results were filtered by ‘clinical tri-
als’ and limitations were ‘English, French, Dutch or
German language’.
From this search, we only included articles specific-
ally addressing the effects of a supervised exercise
training program in patients with pulmonary hyperten-
sion. In addition, the reference lists from published ori-
ginal and review articles were searched manually to
identify other possible eligible studies. Embase, SPORT-
Discus and The Cochrane Central Register of Controlled
Trials were furthermore consulted with the same search
terms.
Studies were included in the meta-analysis if they
were: Controlled trials 1) including a comparative con-
trol group and an intervention group; 2) with an inter-
vention program of at least 3 weeks duration; 3) in
patients groups of which at least 80% is diagnosed with
PAH as defined according to the updated clinical classi-
fication of pulmonary hypertension [1]; 4) reporting pre-
and post-intervention mean and standard deviation (SD)
(or standard error) of 6 minute walking distance in inter-
vention and control groups or mean change and stand-
ard deviation (or standard error) in intervention and
control groups; 5) published in a peer-reviewed journal
up to December 2013. Exclusion criteria included any
studies not meeting all criteria described above.Outcomes
The primary outcome measure was change in 6 minute
walking distance (6MWD). Secondary outcomes included
changes in peak oxygen uptake (peak VO2), peak heart
rate and World Health Organization Functional Class
(WHO-FC).
Data extraction
A specific developed data extraction sheet was used to
extract data on study source, study design, study quality,
sample size, characteristics of the participants, exercise
interventions, and the different outcomes in each study
included in the meta-analysis. Data were extracted by
the first two authors (RB and AA) independently from
each other. The overall agreement rate prior to correct-
ing discrepant items was 0.64. Disagreements were re-
solved by consensus.
Study quality
Study quality was assessed using an adapted PEDro-scale
[8]. This 11-item questionnaire is designed to collect
data on eligibility criteria, random allocation, concealed
allocation, similarity of baseline values, blinding of ther-
apists and/or assessors, key outcomes, intention-to-treat
analysis, between group differences, and point and vari-
ability measures. The quality criteria ‘blinding of partici-
pants’ and ‘blinding of therapists’ were omitted, since
they were not applicable in the included intervention
studies. All questions were binary. The minimum score
was 0 and the maximum was 8, with a higher number
reflecting a better study quality. The PEDro-scale has been
reported to be valid and reliable [9,10]. Using Cohen’s
kappa statistic, overall inter-rater agreement was 0.73. Dis-
agreements were resolved by consensus. Trials were not
excluded based on quality.
Statistical analysis
Excel 2010 and Review Manager Software (RevMan 5.1;
Cochrane Collaboration, Oxford, UK) were used for stat-
istical analyses. Descriptive data are reported as mean ±
standard deviation (SD) or median and range. The mean
baseline values were calculated by combining mean values
from the intervention and control groups, weighted by the
number of participants in the final analysis in each study
group.
Effect sizes for primary and secondary outcomes were
calculated by subtracting the pre-intervention value
from the post-intervention value for both study groups.
The net treatment effect was then obtained by subtract-
ing the change score difference in the control group
from the change score difference of the intervention
group. Review Manager Software calculated the variances
from the inserted pooled SDs of change scores in the
intervention and control groups. However, some studies
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line and post-intervention. Therefore, change scores SDs
that were missing in these studies were calculated from
pre and post SD values, using the following formula:
SDchange = √[(SDpre)2 + (SDpost)2 − 2 × corr(pre,post) ×
SDpre × SDpost] [11], for which a correlation coefficient
of 0.5 between the pre and post values was assumed. The
primary and secondary outcomes were combined using
random-effects models, a preferred approach that incor-
porates heterogeneity into the model [12,13]. Each effect
size was weighted by the inverse of its variance. The re-
sults are reported as weighted means and 95% confidence
intervals (CI). Two sided tests for overall effects were con-
sidered significant at p ≤ 0.05.
Statistical heterogeneity among the trials was assessed
using Cochrane’s Q statistic and an alpha value for statis-
tical significance of 0.10 indicated significant heterogen-
eity. In addition, we report I2 statistics, which assesses
consistency of treatment effects across trials. I2 between
25% and 50% represents small amounts of inconsistency,
whereas between 50-75% and >75% represents medium to
large amounts of heterogeneity [14]. To examine the influ-
ence of each study on the overall results, sensitivity ana-
lyses were also performed with each study deleted from
the model once. Finally, funnel plots were used to assess
the potential of small publication bias. Funnel plot asym-
metry was evaluated by use of Begg and Egger tests, and a
significant publication bias was considered if the p value
was <0.10. The trim and fill computation was used to esti-
mate the effect of publication biases on the interpretation
of the results.Results
Literature search
A PRISMA flow diagram of the literature search and se-
lection is presented in Figure 1. From 110 potentially
relevant studies retrieved from the search, only 6 trials
met our inclusion criteria. However, two studies [15,16]
used the same population and intervention, of which we
included the most complete publication in terms of pri-
mary and secondary outcomes [15].Characteristics of the participants and study designs
A summary of the included studies is provided in
Table 1. Four of the five studies were randomized clin-
ical trials, the other one was a non-randomized clinical
trial. Four studies used a parallel design; the remaining
one used a cross-over design. All studies were published
between 2006 and 2013. The exercise intervention and
control groups consisted each of 53 participants. The re-
sults of the adapted PEDro-scale, used to evaluate study
quality, are presented in Table 2. The median PEDro
score was 6, with a range from 3 [17] to 8 [18].In total, 5 patients dropped out from the studies,
resulting in a total of 101 participants (28 men) that
could be included in the final analysis: 50 of them com-
pleted an exercise intervention and 51 were control sub-
jects. Four studies included a ‘usual care’ control group
(17-20) and in one study, control group participants re-
ceived an educational program [15].
Baseline characteristics of the study participants are
summarized in Table 3. All trials included both men and
women, except for Chan who, by chance, included only
women [15].
Intervention characteristics
Table 1 also provides a description of the intervention
characteristics of each trial. Study duration ranged be-
tween 3 and 15 weeks (median 12). The frequency of ex-
ercise training varied between 2 and 5 sessions weekly
(median 3), with an average duration of 46 min per ses-
sion (range 30-60). The average intensity was between
60 and 80% of peak heart rate in four studies [17-20],
and 70-80% of heart rate reserve in the remaining study
[15]. Mode of exercise was aerobic interval training
along with resistance exercises in 3 trials [17,18,20], sup-
plemented with respiratory training in two of them: Fox
et al. adopted a training program with continuous aer-
obic exercises and resistance exercise [19] whereas Chan
et al. used intensive treadmill exercise training [15].
Assessment of primary and secondary outcomes
In all included studies, the 6-minute walk test was per-
formed in accordance with appropriate guidelines [21].
Peak VO2 and peak heart rate were measured in three
studies using a graded maximal exercise test on an up-
right cycle ergometer [19], on a treadmill [15] or on a
supine cycle ergometer [18]. Four out of the five studies
reported the WHO-FC before and after the intervention.
Mean effect sizes and Z-scores are summarized in
Table 4.
Changes in 6MWD
As shown in Figure 2, 6MWD increased significantly fol-
lowing exercise with a mean increase of 72.2 m (95% CI
45.7 to 98.6; p < 0.001); heterogeneity and inconsistency
were small (Q = 5.72, p = 0.22; I2 = 30%). When each trial
was deleted from the model once, the results remained
statistically significant.
Secondary outcomes
Figure 3 shows the mean changes in peak VO2 with
training. Peak VO2 increased significantly by exercise
training (p = 0.02). However, when the largest study [18]
was deleted from the model, statistical significance could
not be met anymore.
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Figure 1 PRISMA flow chart of the literature search. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097
For more information, visit www.prisma-statement.org.
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ing could not be documented (p = 0.54).
Two out of the four studies who reported WHO-FC,
documented a functional improvement as assessed by
this instrument, but overall no significant reduction of
WHO-FC was induced by exercise training (p = 0.12).
Publication bias
According to the tests of Begg and Egger, funnel plots of
6MWD and peak VO2 did not show any signs of sig-
nificant publication bias (p > 0.5 for all). Duval and
Tweedie’s trim and fill method indicated that one (for
6MWD) or two (peak VO2) studies could be missing at
the right side of the mean effect size. Adjustment of the
data for these missing data did not change the results.
(see Additional files 1 and 2).Discussion
This systematic review and meta-analysis is the first to
focus on the effect of exercise training on physical fit-
ness and functional capacity in patients with PAH. The
analysis, in which 5 studies could be included, showed
that exercise training can result in clinically relevant im-
provements of physical and functional capacity.
The idea that exercise training programs may poten-
tially be beneficial for patients with PAH became only
recently accepted [1]. Exercise based rehabilitation for
patients with PAH is now considered as a new adjunct
treatment option in order to improve their functional
capacity and quality of life. Following here, some proof
of concept studies have been performed; most of them
showing significant beneficial effects of exercise training
on functional capacity and/or exercise capacity, but not
Table 1 Description of the patient populations and characteristics of the exercise training programs
Author Year Origin Design Patient population NYHA Age
(year)
Number at baseline Exercise intervention Control Assessment
of physical
fitness
Mereles et al. 2006 Germany Cross-over PAH (80%) or
chronic pulmonary
thromboembolic
disease (20%)
II - IV 50 Intervention: 15
(10 female/5 male);
Control: 15
(10 female/5 male)
3 weeks in-hospital + 12 weeks home-based
aerobic interval training along with resistance
and respiratory exercises, 5 sessions/week,
30-60 min/session, 60-80% of peak HR
Usual care 6MWT, CPET
Martinez-Quintana et al. 2010 Spain Parallel PAH associated
with congenital
heart disease
II - IV 27.7 Intervention: 4
(2 female/2 male);
Control: 4
(3 female, 1 male)
3 months supervised aerobic interval training
and resistance exercise, 2 sessions/week,
30-60 min/session, 60-80% of peak HR
Usual care 6MWT
Fox et al. 2011 Israel Parallel PAH (91%) or chronic
thromboembolic
PH (9%)
II - III 51.5 Intervention: 11
(10 female/1 male);
Control: 11
(5 female, 6 male)
3 months supervised continuous aerobic
and resistance exercise, 2 sessions/week,
60 min/session, 60-80% of peak HR
Usual care 6MWT, CPET
Ley et al. 2013 Germany Parallel PAH (80%) or
chronic inoperable
tromboembolic
PH (20%)
II - III 50.5 Intervention: 10
(8 female/2 male);
Control: 10
(6 female, 4 male)
3 weeks supervised aerobic interval training
along with resistance and respiratory
exercises, 5 sessions/week, 30-60 min/
session, 60-80% of peak HR
Usual care 6MWT
Chan et al. 2013 USA Parallel PAH I - IV 54.4 Intervention: 13
(13 female/0 male);
Control: 13
(13 female, 0 male)
10 weeks supervised treadmill walking,
3 sessions/week, 30-45 min/session,
70-80% of heart rate reserve + patient
education
Patient
education
only
6MWT, CPET
6MWT = 6-minute walking test; CPET = cardiopulmonary exercise testing; PAH = pulmonary arterial hypertension; PH = pulmonary hypertension.
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Table 2 PEDro-scores for the intervention trials included in the meta-analysis
Study (year) Eligibility
criteria
Randomly
allocated
Allocation
concealed
Baseline
similar
Blinding
assessors
Key
outcome
85%
Intention
to treat
Between
group
Point and
variability
measure
Total PEDro
score
Mereles (2006) 1 1 1 1 1 1 1 1 1 8
Martinez-Quintana (2010) 1 0 0 0 0 1 0 0 1 2
Fox (2011) 1 0 1 0 1 1 1 1 1 6
Ley (2013) 1 1 0 1 0 1 0 1 1 5
Chan (2013) 1 1 1 1 1 0 1 1 1 7
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Hence, the existing evidence is inconclusive and insuffi-
cient to result in the implementation of exercise pro-
grams in routine clinical care for patients with PAH. By
pooling data from published controlled trials, we aimed
to increase the statistical power and resolve the uncer-
tainty. We could show that exercise training is effective
for improving both functional and exercise capacity.
In todays practice the 6MWD is most often used as
an endpoint to assess the benefit of therapies in PAH. It
is a measure of functional capacity. This meta-analysisTable 3 Baseline characteristics of the study participants
Variable Exercise Control
Patients (n) 53
(40 F, 10 M)
53
(35 F, 18 M)
Mean age (years) 48.5 50.8
Pulmonary hypertension diagnosis (n)
PAH 50 46
Ideopathic PAH 12 14
Hereditary PAH 0 1
PAH associated with congenital
heart disease
5 4
PAH associated with connective
tissue disease
14 14
PAH associated with portal hypertension 1 1
Drug induced PAH 0 1
PAH subtype not specified 16 11
Chronic thromboembolic pulmonary
hypertension
3 7
WHO-FC (n)
Class I 1 0
Class II 12 13
Class III 24 28
Class IV 2 1
Not reported (Fox et al.) 11 11
Mean pulmonary artery pressure (mmHg)* 49 47.1
6 minute walking test distance (m) 401 408
n = number; PAH: pulmonary arterial hypertension; WHO-FC =World Health
Organization Functional Class.
*Not reported in Martinez-Quintana et al, mean of 4 remaining studies.documented that an exercise training program of around
12 weeks can significantly improve the 6MWD with 72 m
on average. This gain in walking distance is larger than
that reported for patients with chronic obstructive pul-
monary disease [22,23] or chronic heart failure [24].
Whereas it remains to be determined which minimum in-
crease in 6MWD has to be reached in patients with PAH
in order to obtain a clinically relevant improvement, a
change of more than 50 meters has been proposed as
representative of a clinically meaningful change in most
disease states [25]. On the other hand, short-term im-
provements in 6MWD due to medical treatment could so
far not be related to an improved longer-term prognosis
[26] even though a baseline distance less than approxi-
mately 330 m on the 6MWD has been shown to be associ-
ated with increased mortality in PAH [27]. In line with
these results, Golpe and colleagues in non-group 1 PAH
patients reported that a distance less than 400 m was pre-
dictive of a significantly worse prognosis [28]. In our
study, mean baseline 6MWD was already more than 400
meter, however it is anticipated that the average observed
gain in 6MWD of 72 m due to exercise training, will have
shifted a part of the weaker patients towards a 6MWD
larger than 400 m and thus towards a more favorable
prognosis.
Overall, cardiopulmonary exercise testing is the pre-
ferred method for assessing changes associated with
exercise training [29]. Despite being less often used, car-
diopulmonary exercise testing should also be considered
as the gold standard measurement of exercise capacityTable 4 Effect sizes of primary and secondary outcomes
of the meta-analysis
Variable Study
groups
n Mean effect size
(95% CI)
Z (p)
6 minute walking
test distance (m)
5 101 72.17 [45.71, 98.62] 5,35 (<0,0001)
Peak oxygen uptake
(mL/kg/min)
3 73 2.14 [0.40, 3.88] 2,41 (0,02)
Peak heart rate
(beats/min)
3 75 2.11 [-4.59, 8.81] 0,62 (0,54)
WHO-FC 4 78 -0.24 [-0.44, -0.04] 1,57 (0,12)
n = number; WHO-FC =World Health Organization Functional Class; sPAP = peak
systolic pulmonary artery pressure.
Figure 2 Forest plot of the average net changes and corresponding 95% confidence intervals for 6 minutes walking distance.
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studies reported exercise training related changes in oxy-
gen uptake. Nevertheless, this was already sufficient to
document a small but significant increase in peak VO2
following exercise training. This result is also in line with
several other small-scale non-controlled studies [31] and
adds further evidence to support the use of exercise
training to increase peak VO2 in this patient population.
Whereas the clinical significance of these small improve-
ments (+2.6 ml/min/kg peak VO2) in this population re-
mains inconclusive, Groeppenhof et al. showed that
among patients with PAH, survivors have larger increases
in exercise capacity compared to non-survivors [32].
The underlying mechanisms causing these training ef-
fects might be of both central pulmonary and cardiovas-
cular as well as peripheral origin, but need to be further
clarified. In addition, whether baseline and especially
training-related changes in objective exercise capacity
reflect a better prognosis both in short and longer term
of patients with PAH still needs to be determined [30].
Exercise capacity is closely related to the ability to per-
form normal daily life activities. In turn, this closely
relates to quality of life. Exercise tests can indirectly
quantify shortness of breath and fatigue, two of the most
common symptoms of PAH. Therefore, the change in
6MWD and peak VO2 from baseline to the end of an ex-
ercise training program might suggest symptomatic im-
provement over that time-period [33]. Although we
could only show a tendency (p = 0.12) toward a func-
tional improvement by means of the WHO-FC scale,
this was only based on four studies and more studies areFigure 3 Forest plot of the average net changes and corresponding 95% cwarranted. Moreover, the effect of exercise training on
quality of life in these patients needs further research
due to the importance for both clinicians and patients.
Limitations
There are several limitations to our work. Although
meta-analyses are no substitute for large well-designed
controlled trials, the meta-analytical technique is prob-
ably the best method to systematically review previous
work. Advantages are the greater precision of the esti-
mates and the enhanced statistical power. In order to
provide the most accurate summary of the effects of ex-
ercise training for PAH, the PRISMA statement was
carefully followed [34]. A potential disadvantage of a
meta-analysis is the heterogeneity of studies for instance
due to variations in the exercise programs and the dif-
ferences between patient populations [35]. Although
random-effects models which incorporate heterogeneity
into their model were used, some caution might be war-
ranted with the interpretation given also the small num-
ber of studies and the small sample sizes. Further, as
there were only 3 randomized trials, we also included 2
non-randomized studies. The results of those may be af-
fected by confounding bias due to the absence of ran-
dom assignment.
Conclusions
The findings from this systematic review and meta-
analysis suggest that an exercise training program posi-
tively influences exercise tolerance and functional capacity
in patients with PAH. Physicians need to become aware ofonfidence intervals for peak oxygen uptake.
Buys et al. BMC Pulmonary Medicine  (2015) 15:40 Page 8 of 9the positive effects of this non-pharmacological interven-
tion that can improve the integrated care of patients with
PAH. Given the small number of available studies and the
small sample sizes, we believe that this topic deserves a
more in-depth investigation. Well-designed randomized
clinical trials investigating the effects of exercise training
on exercise capacity and patient outcomes are needed to
confirm our results.
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